Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration.

PUBLICATION:

Journal Article

Authors:

Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, Kharel MK, Guo H, Marsh JL, Thompson LM, Mahishi L, Ahuja P, MacLellan WR, Geschwind DH, Coppola G, Rohr J, Ratan RR.

Year Published:

2011

Publisher:

J Neurosci. 2011 May 4;31(18):6858-70. doi: 10.1523/JNEUROSCI.0710-11.2011. Erratum in: J Neurosci. 2012 May 9;32(19):6743.

Identifiers:

PMID:21543616 | PMCID:PMC3717375

Full-Text on PubMed

Featured Researchers

Brett C. Langley, Ph.D.

Former Lab Director

Neuronal Epigenetics Laboratory

Associate Professor

University of Waikato

Rajiv R. Ratan, M.D., Ph.D.

Chief Executive Officer

Burke Professor, Associate Dean (affiliate)

Weill Cornell Medicine

You are here

Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration.

Featured Researchers

Associated

Conditions & Recovery

Research Methods